Abstract
Since the conception of RNA nanotechnology (Cell, 94:147, 1998), there has been tremendous interest in its application for the functional delivery of RNA into cells. Splice-switching oligonucleotides (SSOs) are an emerging antisense drug class with the ability to therapeutically modify gene expression. A wide variety of chemical modifications have been devised to try to increase the activity and stability of SSOs. Also, as with most nucleic acid therapeutics, delivery into the cell is the major hurdle for in vivo and clinical applications. As a result, various RNA nanoparticles are being constructed for targeted delivery of therapeutics. However, it is difficult to find a practical assay to measure splice-switching activity. Here, we describe a model delivery system that can be used as a convenient, high-throughput assay to quantitatively measure the functional delivery and splicing redirection in a live human melanoma cell line.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wang ET, Sandberg R, Luo S et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470–476
Lopez-Bigas N, Audit B, Ouzounis C et al (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579:1900–1903
Bauman J, Li S, Yang A et al (2010) Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 38(22):8348–8356
van Deutekom J, Janson A, Ginjaar I et al (2007) Local dystrophin restoration with antisense oligonucleotide. N Engl J Med 357:2677–2686
Mann C, Homeyman K, Cheng A et al (2000) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98(1):42–47
Chan J, Lim S, Wong W (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33:533–540
Bauman J, Jearawiriyapaisarn N, Kole R (2009) Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 19(1):1–13
Kurreck J (2003) Antisense technologies: improvement through novel chemical modifications. Eur J Biochem 270:1628–1644
Guo P, Zhang C, Chen C et al (1998) Inter-RNA interaction of phage φ29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell 2:149–155
Shu Y, Pi F, Sharma A et al (2014) Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev 66:74–89
Kang S, Cho M, Kole R (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37(18):6235–6239
Mäe M, Samir E, Lundin P et al (2009) A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 134:221–227
Kotula J, Pratico E, Ming X et al (2012) Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther 22:187–195
Abes S, Williams D, Prevot P et al (2006) Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release 110:595–604
El-Andaloussi S, Johansson H, Lundberg P et al (2006) Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 8:1262–1273
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Dean, J.M., DeLong, R.K. (2015). A High-Throughput Screening Assay for the Functional Delivery of Splice-Switching Oligonucleotides in Human Melanoma Cells. In: Guo, P., Haque, F. (eds) RNA Nanotechnology and Therapeutics. Methods in Molecular Biology, vol 1297. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2562-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2562-9_13
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2561-2
Online ISBN: 978-1-4939-2562-9
eBook Packages: Springer Protocols